Frontlight ResearchEarly access
CompletedEarly phase 1
Pharmacokinetics of Atropine Oral Gel
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 10 people enrolled
- Started
- 1 Oct 2022
- Ended
- 10 Dec 2024
- Type of study
- Interventional
- Treatments tested
- Atropine sulfate gel (0.01%)
- Record updated
- 18 December 2024
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Provide written informed consent and authorization
- Study participants must be able to complete consent, and all study evaluations written in the English language
Who cannot take part
- Chemotherapy or radiotherapy treatment within the last three months
- Previous head and/or neck radiotherapy
- Treatment with any other investigational drug during the 30 days prior to enrollment into the study
- Patients receiving anticholinergic medications at baseline
- Patients who are receiving immunosuppression
- Patient taking monoamine oxidase inhibitors
- Patients with a history of hypersensitivity reaction towards atropine and/or Carbopol 980 NF or any carbomers
- Patients with heart conditions such as congenital heart disease, heart failure, coronary heart disease, myocardial infarction, and arrhythmia
- Patients with partial pyloric stenosis or other diseases related to gastrointestinal obstruction
- Patients who are actively being treated for an infection
- Patients with a history of salivary gland obstruction or stones
- Patients with a history of chronic lung disease or chronic obstructive pulmonary disease (COPD)
- Severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated using the CKD-EPI creatinine equation:; eGFR (mL/min/1.73 m2) = 141 x min(Scr/k, 1)α x max(Scr/k,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]; Where,; k=0.7 if female; k=0.9 if male; α=-0.329 if female; α=-0.411 if male; min=The minimum of Scr/k or 1; max=The maximum of Scr/k or 1; Scr = serum creatinine (mg/dL)
- Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:; Bilirubin > 3 x upper limit of normal (ULN). [ULN for bilirubin = 1.4 mg/dL]; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 x ULN values used by the laboratory performing the test. [ULN for AST = 40 U/L, ULN for ALT = 60 U/L]; Alkaline phosphatase (ALP) > 3 x ULN [ULN for ALP = 126 U/L)
- Female subjects who are pregnant or nursing at the time of screening
- Deforming lesions of the oral cavity
- Patients with acute glaucoma that may be exacerbated with atropine administration
- Patients diagnosed with urinary retention
- Patients with an artificial airway (tracheostomy)
Where in United States
- University of UtahSalt Lake City, United States
About the trial
What the trial wants to find out
To evaluate the single-dose pharmacokinetics of atropine gel formulation after topical administration in the oral cavity of healthy adults.
The group in the trial
- 0.1 mg of atropineTreatment being tested
1 gram of gel by topical application in the oral cavity once.
Treatment: Atropine sulfate gel (0.01%)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Single-Dose Pharmacokinetics of Atropine Oral Gel in Healthy Adults
- Record updated
- 18 December 2024